Gilead sciences - long term investment
Mis à jour
Dear traders and followers,
It’s time again for one of our popular stock analytics. Today we take a closer look at Gilead Sciences
The California-based pharmaceutical and biotechnology company offers a very attractive mix of Corona’s special economy, a bit of takeover fantasy and a moderate evaluation. The drug Remdesivir, which is approved for Corona treatment, is expected to generate sales of almost two billion dollars this year, which according to Bloomberg’s 2021 estimate should increase by another 20 percent. The 2021 KGV of eleven is among the ten lowest in the entire Nasdaq 100. No wonder there is speculation that AstraZeneca wants to take over Gilead, given that both groups are complementary in their focus areas. If this is not enough as a reason to buy, the share traded around 40 percent below the record high looks at the nice lower reversal, which can be seen in the chart picture along with the medium-term upward trend.
Technical view:
Market has formed a triangle formation since 2014 (after a strong up rally) and broke out of it at the beginning of March. The price is atm within correction movement which is expected to end at the drawn buy area at around 70 $. We´ve set our buy orders at this point.
Feel free to leave a comment or to share your ideas in the comments section
Please hit the like button if you share or like this idea.
Thanks for your support !
It’s time again for one of our popular stock analytics. Today we take a closer look at Gilead Sciences
The California-based pharmaceutical and biotechnology company offers a very attractive mix of Corona’s special economy, a bit of takeover fantasy and a moderate evaluation. The drug Remdesivir, which is approved for Corona treatment, is expected to generate sales of almost two billion dollars this year, which according to Bloomberg’s 2021 estimate should increase by another 20 percent. The 2021 KGV of eleven is among the ten lowest in the entire Nasdaq 100. No wonder there is speculation that AstraZeneca wants to take over Gilead, given that both groups are complementary in their focus areas. If this is not enough as a reason to buy, the share traded around 40 percent below the record high looks at the nice lower reversal, which can be seen in the chart picture along with the medium-term upward trend.
Technical view:
Market has formed a triangle formation since 2014 (after a strong up rally) and broke out of it at the beginning of March. The price is atm within correction movement which is expected to end at the drawn buy area at around 70 $. We´ve set our buy orders at this point.
Feel free to leave a comment or to share your ideas in the comments section
Please hit the like button if you share or like this idea.
Thanks for your support !
Transaction en cours
Buy entry active at 65 $
The analyses provided are for informational purposes only and do not constitute financial advice or recommendations to buy or sell anything. The information presented is based on personal research and interpretation.
Clause de non-responsabilité
Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.